SOSEI CO LTD. SOLTF news, videos and press releases
For more news please use our advanced search feature.
SOSEI CO LTD. SOLTF - More news...
SOSEI CO LTD. SOLTF - More news...
- Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
- Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
- Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
- Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
- Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
- Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
- Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
- Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
- Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
- Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
- Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023
- Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
- Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
- Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
- Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
- Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
- Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
- Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea
- Nxera Pharma joins the World Orphan Drug Alliance
- Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC
- Nxera Pharma is the New Name for Sosei Group
- Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
- Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
- Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
- Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
- Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
- Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
- Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
- Sosei Heptares Webinar Presentation for FY2023 Financial Results
- Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer
